Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. more
Time Frame | RXRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17.9% | -2.06% | -0.55% |
1-Month Return | 1.89% | -1.92% | 2.72% |
3-Month Return | -10.06% | -10.4% | 7.66% |
6-Month Return | -35.93% | -4.6% | 10.15% |
1-Year Return | -34.23% | 4.06% | 27.53% |
3-Year Return | -67.78% | 1.94% | 32.31% |
5-Year Return | -80.14% | 36.48% | 89.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.71M | 3.41M | 10.00M | 39.68M | 44.58M | [{"date":"2019-12-31","value":3.84,"profit":true},{"date":"2020-12-31","value":7.66,"profit":true},{"date":"2021-12-31","value":22.43,"profit":true},{"date":"2022-12-31","value":89.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 45.81M | 63.32M | 9.10M | 48.27M | 42.59M | [{"date":"2019-12-31","value":72.35,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":14.38,"profit":true},{"date":"2022-12-31","value":76.24,"profit":true},{"date":"2023-12-31","value":67.26,"profit":true}] |
Gross Profit | (44.10M) | (59.91M) | 10.00M | (8.59M) | 1.99M | [{"date":"2019-12-31","value":-440.98,"profit":false},{"date":"2020-12-31","value":-599.06,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-85.94,"profit":false},{"date":"2023-12-31","value":19.88,"profit":true}] |
Gross Margin | (2577.32%) | (1755.23%) | 100.00% | (21.66%) | 4.46% | [{"date":"2019-12-31","value":-2577.32,"profit":false},{"date":"2020-12-31","value":-1755.23,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-21.66,"profit":false},{"date":"2023-12-31","value":4.46,"profit":true}] |
Operating Expenses | 64.15M | 88.03M | 192.78M | 237.13M | 352.05M | [{"date":"2019-12-31","value":18.22,"profit":true},{"date":"2020-12-31","value":25,"profit":true},{"date":"2021-12-31","value":54.76,"profit":true},{"date":"2022-12-31","value":67.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (62.44M) | (84.61M) | (182.78M) | (245.73M) | (350.06M) | [{"date":"2019-12-31","value":-6244100000,"profit":false},{"date":"2020-12-31","value":-8461500000,"profit":false},{"date":"2021-12-31","value":-18277500000,"profit":false},{"date":"2022-12-31","value":-24572700000,"profit":false},{"date":"2023-12-31","value":-35006000000,"profit":false}] |
Total Non-Operating Income/Expense | 1.67M | (3.42M) | (6.58M) | 12.45M | 36.12M | [{"date":"2019-12-31","value":4.62,"profit":true},{"date":"2020-12-31","value":-9.45,"profit":false},{"date":"2021-12-31","value":-18.22,"profit":false},{"date":"2022-12-31","value":34.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (61.88M) | (87.01M) | (186.48M) | (239.48M) | (332.13M) | [{"date":"2019-12-31","value":-6187900000,"profit":false},{"date":"2020-12-31","value":-8700600000,"profit":false},{"date":"2021-12-31","value":-18647900000,"profit":false},{"date":"2022-12-31","value":-23947600000,"profit":false},{"date":"2023-12-31","value":-33212800000,"profit":false}] |
Income Taxes | 646.00K | 876.00K | (8.40M) | (55.00K) | (4.06M) | [{"date":"2019-12-31","value":73.74,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-959.47,"profit":false},{"date":"2022-12-31","value":-6.28,"profit":false},{"date":"2023-12-31","value":-463.7,"profit":false}] |
Income After Taxes | (62.52M) | (87.88M) | (178.07M) | (239.42M) | (328.07M) | [{"date":"2019-12-31","value":-6252500000,"profit":false},{"date":"2020-12-31","value":-8788200000,"profit":false},{"date":"2021-12-31","value":-17807400000,"profit":false},{"date":"2022-12-31","value":-23942100000,"profit":false},{"date":"2023-12-31","value":-32806600000,"profit":false}] |
Income From Continuous Operations | (61.88M) | (87.01M) | (186.48M) | (239.48M) | (292.56M) | [{"date":"2019-12-31","value":-6187900000,"profit":false},{"date":"2020-12-31","value":-8700600000,"profit":false},{"date":"2021-12-31","value":-18647900000,"profit":false},{"date":"2022-12-31","value":-23947600000,"profit":false},{"date":"2023-12-31","value":-29256200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (62.52M) | (87.88M) | (178.07M) | (239.42M) | (328.07M) | [{"date":"2019-12-31","value":-6252500000,"profit":false},{"date":"2020-12-31","value":-8788200000,"profit":false},{"date":"2021-12-31","value":-17807400000,"profit":false},{"date":"2022-12-31","value":-23942100000,"profit":false},{"date":"2023-12-31","value":-32806600000,"profit":false}] |
EPS (Diluted) | - | (0.25) | (2.30) | (1.37) | (1.57) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-25,"profit":false},{"date":"2021-12-31","value":-230,"profit":false},{"date":"2022-12-31","value":-137,"profit":false},{"date":"2023-12-31","value":-157,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RXRX | |
---|---|
Cash Ratio | 3.93 |
Current Ratio | 4.35 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RXRX | |
---|---|
ROA (LTM) | -36.40% |
ROE (LTM) | -78.49% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RXRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.28 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.72 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RXRX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 37.25 |
P/B | 4.63 |
Price/FCF | NM |
EV/R | 32.37 |
EV/Ebitda | NM |
Recursion Pharmaceuticals Inc (RXRX) share price today is $6.215
Yes, Indians can buy shares of Recursion Pharmaceuticals Inc (RXRX) on Vested. To buy Recursion Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RXRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Recursion Pharmaceuticals Inc (RXRX) via the Vested app. You can start investing in Recursion Pharmaceuticals Inc (RXRX) with a minimum investment of $1.
You can invest in shares of Recursion Pharmaceuticals Inc (RXRX) via Vested in three simple steps:
The 52-week high price of Recursion Pharmaceuticals Inc (RXRX) is $15.74. The 52-week low price of Recursion Pharmaceuticals Inc (RXRX) is $5.6.
The price-to-earnings (P/E) ratio of Recursion Pharmaceuticals Inc (RXRX) is
The price-to-book (P/B) ratio of Recursion Pharmaceuticals Inc (RXRX) is 4.63
The dividend yield of Recursion Pharmaceuticals Inc (RXRX) is 0.00%
The market capitalization of Recursion Pharmaceuticals Inc (RXRX) is $2.89B
The stock symbol (or ticker) of Recursion Pharmaceuticals Inc is RXRX